Abstract 6149: Relationship of Metabolic Syndrome to Incident Aortic Valve Calcium and Aortic Valve Calcium Progression: The Multi-Ethnic Study of Atherosclerosis
Metabolic syndrome (MetS) recently has been associated with increased risks for prevalent aortic valve calcium (AVC), aortic stenosis progression, and bioprosthetic aortic valve degeneration. However, it is not known whether MetS is associated with increased risks for the development of new (“incident”) AVC or for progression of established AVC, as assessed by serial computed tomography (CT) scans. The relationships of MetS or its components, as well as of diabetes mellitus (DM) to risks for incident AVC or AVC progression were studied among participants with CT scans performed at baseline and at either Year 2 or Year 3 examinations in the Multi-Ethnic Study of Atherosclerosis (MESA). Of 5,723 MESA participants meeting criteria for inclusion, 1,674 had MetS by Adult Treatment Panel (ATP) III criteria, while 761 had DM. Among the 5,123 participants without baseline AVC, risks for incident (“new”) AVC were increased significantly for MetS in men (adjusted OR 1.93, 95% CI 1.24 to 3.00) or DM (adjusted OR 2.27, 95% CI 1.35 to 3.83), but not in women. Among the 600 participants with baseline AVC, MetS was associated with significantly increased AVC progression in men [median Agatston AVC score increase = 13.1 (95% CI 3.4 to 26.5) Agatston units/year, p<0.05], but not in women. In the MESA cohort, MetS was associated with significant increases in both incident (“new”) AVC and AVC progression in men, raising the possibility that MetS may be a potential therapeutic target to prevent AVC development or to inhibit its progression.